Nemudraia, Anna
Nemudryi, Artem http://orcid.org/0000-0003-0121-1363
Buyukyoruk, Murat
Scherffius, Andrew M.
Zahl, Trevor
Wiegand, Tanner http://orcid.org/0000-0002-0528-268X
Pandey, Shishir
Nichols, Joseph E.
Hall, Laina N.
McVey, Aidan
Lee, Helen H.
Wilkinson, Royce A. http://orcid.org/0000-0001-8831-2081
Snyder, Laura R.
Jones, Joshua D. http://orcid.org/0000-0002-8811-1340
Koutmou, Kristin S. http://orcid.org/0000-0002-7763-9262
Santiago-Frangos, Andrew http://orcid.org/0000-0001-9615-065X
Wiedenheft, Blake http://orcid.org/0000-0001-9297-5304
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (1K99AI171893-01)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM128836, 1K99GM147842, R35GM134867)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Article History
Received: 18 March 2022
Accepted: 5 December 2022
First Online: 15 December 2022
Competing interests
: B.W. is the founder of SurGene LLC, and VIRIS Detection Systems Inc. B.W., A. Nemudryi, A. Nemudraia, and A.S.-F. are inventors of the patent applications US17/240858 and PCT/US2021/029219 pertaining to use of engineered type III CRISPR-Cas system for sensitive and sequence-specific detection of nucleic acids filed by Montana State University. The remaining authors declare no competing interests.